HEALTHY U MEDICAID

PRIOR AUTHORIZATION REQUEST FORM

CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) AGENTS

Kalydeco®, Orkambi®, Symdeko®, Trikafta™

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested:		7								
Office Phone: Office Pax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Kalydeco® (ivacaftor),	Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.									
Office Phone: Office Pax: Office Contact: Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: Kalydeco® (ivacaftor),										
Office Phone: Description Description	Date	e:	Member Name:		ID#:					
Height/Weight: Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: □ Kalydeco® (ivacaftor), □ Orkambi® (lumacaftor/ivacaftor), □ Symdeko® (tezacaftor/ivacaftor and ivacaftor), □ Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Dosing/Frequency: If the request is for reauthorization, proceed to reauthorization section. Questions Yes No Comments/Notes 1. Does the member have a documented diagnosis of cystic fibrosis (CF) as listed below? ○ Cystic fibrosis with pulmonary manifestations ○ Cystic fibrosis with other intestinal manifestations ○ Cystic fibrosis with other manifestations ○ Cystic fibrosis, unspecified 2. Is the requesting provider a cystic fibrosis specialist? 3. Does the provided documentation show that the member has a □ □ Please provide documentation CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of □ Please provide documentation	DOE	3:	Gender:		Phy	sician:				
Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: □ Kalydeco® (ivacaftor), □ Orkambi® (lumacaftor/ivacaftor), □ Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor) Symdeko® (tezacaftor/ivacaftor and ivacaftor) If the request is for reauthorization, proceed to reauthorization section. Questions Yes No Comments/Notes Please provide documents/Notes 1. Does the member have a documented diagnosis of cystic fibrosis (CF) as listed below?	Offic	fice Phone: Office Fax:			Office Contact:					
preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested:	Heig	Height/Weight:								
Questions Yes No Comments/Notes 1. Does the member have a documented diagnosis of cystic fibrosis (CF) as listed below? Cystic fibrosis with pulmonary manifestations Cystic fibrosis with other intestinal manifestations Cystic fibrosis with other manifestations Cystic fibrosis, unspecified □ 2. Is the requesting provider a cystic fibrosis specialist? □ 3. Does the provided documentation show that the member has a CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? □ Please provide documentation 5. Does the member demonstrate at least a 75% history of □ Please provide documentation	preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Product being requested: □ Kalydeco® (ivacaftor), □ Orkambi® (lumacaftor/ivacaftor), □ Symdeko® (tezacaftor/ivacaftor and ivacaftor), □ Trikafta™ (elexacaftor/tezacaftor/ivacaftor and ivacaftor)									
1. Does the member have a documented diagnosis of cystic fibrosis (CF) as listed below? • Cystic fibrosis with pulmonary manifestations • Cystic fibrosis with other intestinal manifestations • Cystic fibrosis with other manifestations • Cystic fibrosis, unspecified 2. Is the requesting provider a cystic fibrosis specialist? 3. Does the provided documentation show that the member has a CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of Please provide documentation										
fibrosis (CF) as listed below? • Cystic fibrosis with pulmonary manifestations • Cystic fibrosis with other intestinal manifestations • Cystic fibrosis with other manifestations • Cystic fibrosis, unspecified 2. Is the requesting provider a cystic fibrosis specialist? 3. Does the provided documentation show that the member has a CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of Please provide documentation		Questions		Yes	No	Comments/Notes				
 3. Does the provided documentation show that the member has a CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of Please provide documentation Please provide documentation	4 1									
CF mutation that the requested medication is indicated to treat? 4. Does the member have a baseline forced expiratory volume in one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of Please provide documentation		fibrosis (CF) as listed below?Cystic fibrosis with pulmonary mCystic fibrosis with other intestinCystic fibrosis with other manife	nanifestations nal manifestations			Please provide documentation				
one second (FEV1) between 40% and 90% of predicted normal value? 5. Does the member demonstrate at least a 75% history of Please provide documentation	1	 fibrosis (CF) as listed below? Cystic fibrosis with pulmonary m Cystic fibrosis with other intestin Cystic fibrosis with other manife Cystic fibrosis, unspecified 	nanifestations nal manifestations stations			Please provide documentation				
·	2. 1	fibrosis (CF) as listed below? Cystic fibrosis with pulmonary m Cystic fibrosis with other intestir Cystic fibrosis with other manife Cystic fibrosis, unspecified Is the requesting provider a cystic fibroses the provided documentation of the following provided metals on the provided metals of the	nanifestations nal manifestations stations brosis specialist? show that the member has a			·				
compliance with the Cystic Fibrosis Center clinic visits over the last 12 months? Documentation of adherence must be provided with the request.	2. I 3. I 4. I	 fibrosis (CF) as listed below? Cystic fibrosis with pulmonary m Cystic fibrosis with other intestin Cystic fibrosis with other manife Cystic fibrosis, unspecified Is the requesting provider a cystic fi Does the provided documentation of the provided meatreat? Does the member have a baseline fone second (FEV1) between 40% ar 	nanifestations nal manifestations stations brosis specialist? show that the member has a dication is indicated to forced expiratory volume in			Please provide documentation				
6. Does the member demonstrate at least 80% adherence to prescribed medication therapies over the last 12 months? Please provide documentation	2. I 3. I () 1 4. I () 5. I () 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	 fibrosis (CF) as listed below? Cystic fibrosis with pulmonary m Cystic fibrosis with other intestir Cystic fibrosis with other manife Cystic fibrosis, unspecified Is the requesting provider a cystic fibrosis the provided documentation of the provided d	nanifestations nal manifestations stations brosis specialist? show that the member has a dication is indicated to orced expiratory volume in nd 90% of predicted normal east a 75% history of Center clinic visits over the			Please provide documentation Please provide documentation				

	Adherence to prescribed medications will be verified by claim						
	review and fill history, if available.						
REAUTHORIZATION							
	Is the request for reauthorization of therapy?						
2.	Does the member have a continued medical need for therapy and has the therapy been effective and tolerable?			Please provide documentation			
3.	 Has member achieved a clinically significant response to therapy with documentation of at least ONE of the following? Improvement or stabilization in lung function as demonstrated by a current FEV1 as compared to pretreatment values. Improvement or stabilization in Body Mass Index (BMI) as compared to pre-treatment BMI. Member has a decrease in pulmonary exacerbations as demonstrated by a decrease in hospitalizations, emergency room visits and/or IV antibiotic use. 			Please provide documentation			
4.	Is member's ALT or AST not > 5 times the upper limit of normal (UNL) and ALT or AST is not > 3 times the UNL and bilirubin is not > 2 times the UNL?			Please provide documentation			
5.	Does documentation show yearly ophthalmic examinations are performed to assess for possible non-congenital lens opacities for adolescent members between the ages of 12 – 18 years of age?			Please provide documentation			
6.	Did member demonstrate at least 80% adherence to prescribed medication therapies over at least the last 6 months prior to continuation of therapy requests? Adherence to prescribed medications will be verified by claim review and fill history.			Please provide documentation			
7.	Is the member followed at least annually by a practitioner who specializes in the care of patients with cystic fibrosis?						
What medications and/or treatment modalities have been tried in the past for this condition? Please document							
name of treatment, reason for failure, treatment dates, etc.							
Additional information:							
Physician Signature:							

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-HU-014 Origination Date: 01/01/2022 Reviewed/Revised Date: 01/18/2023 Next Review Date: 01/18/2024 Current Effective Date: 02/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.